Cero Therapeutics Holdings, Stock Today
| CERO Stock | 0.91 0.05 5.21% |
PerformanceVery Weak
| Odds Of DistressHigh
|
CERo Therapeutics is selling at 0.91 as of the 23rd of March 2025; that is 5.21 percent decrease since the beginning of the trading day. The stock's open price was 0.96. CERo Therapeutics has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 23rd of December 2024 and ending today, the 23rd of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 15th of February 2024 | Category Healthcare | Classification Health Care |
CERo Therapeutics is entity of United States. It is traded as Stock on NASDAQ exchange. The company has 51.35 M outstanding shares of which 331.03 K shares are currently shorted by private and institutional investors with about 0.23 trading days to cover. More on CERo Therapeutics Holdings,
Moving together with CERo Stock
Moving against CERo Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
CERo Stock Highlights
| Interim Chairman | Christopher MBA | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
CERo Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand CERo Therapeutics' financial leverage. It provides some insight into what part of CERo Therapeutics' total assets is financed by creditors.
| |||||
CERo Therapeutics Holdings, (CERO) is traded on NASDAQ Exchange in USA. It is located in 201 Haskins Way, South San Francisco, CA, United States, 94080 and employs 8 people. CERo Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 4.79 M. CERo Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 51.35 M outstanding shares of which 331.03 K shares are currently shorted by private and institutional investors with about 0.23 trading days to cover.
CERo Therapeutics generates negative cash flow from operations
Check CERo Therapeutics Probability Of Bankruptcy
Ownership AllocationCERo Therapeutics holds a total of 51.35 Million outstanding shares. CERo Therapeutics Holdings, shows 12.54 percent of its outstanding shares held by insiders and 9.04 percent owned by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check CERo Ownership Details
CERo Therapeutics Historical Income Statement
CERo Stock Against Markets
CERo Therapeutics Corporate Executives
Elected by the shareholders, the CERo Therapeutics' board of directors comprises two types of representatives: CERo Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of CERo. The board's role is to monitor CERo Therapeutics' management team and ensure that shareholders' interests are well served. CERo Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, CERo Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Daniel MD | CTO Founder | Profile | |
| Lawrence MD | Cofounder Board | Profile | |
| Charles Carter | Treasurer CFO | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CERo Therapeutics Holdings,. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CERo Therapeutics. If investors know CERo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CERo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of CERo Therapeutics is measured differently than its book value, which is the value of CERo that is recorded on the company's balance sheet. Investors also form their own opinion of CERo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is CERo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CERo Therapeutics' market value can be influenced by many factors that don't directly affect CERo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CERo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if CERo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CERo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.